Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

NCT05812807 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT05812807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05812807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
June 14, 2023
Completion date
May 31, 2033
Enrollment
1,295 (estimated)
Sites
846

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage ii breast cancer ajcc v8, anatomic stage iiia breast cancer ajcc v8, anatomic stage iiib breast cancer ajcc v8, early stage triple-negative breast carcinoma